An experimental Ebola drug healed all 18 monkeys infected with the deadly virus in a study, boosting hopes that the treatment might help fight the outbreak raging through west Africa — once more of it can be made.
The monkeys were given the drug, ZMapp, three to five days after they were infected with the virus and when most were showing symptoms. That is several days later than any other experimental Ebola treatment tested so far.
The drug also completely protected six other monkeys given a slightly different version of it three days after infection in a pilot test. These two studies are the first monkey tests ever done on ZMapp.
“The level of improvement was utterly beyond my honest expectation,” said one study leader, Gary Kobinger of the Public Health Agency of Canada in Winnipeg.
“For animal data, it’s extremely impressive,” said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, which had a role in the work.
It is not known how well the drug would work in people, who can take up to 21 days to show symptoms and are not infected the way the lab monkeys were.
Several experts said it is not possible to estimate a window of opportunity for treating people, but that it was encouraging that the animals recovered when treated even after advanced disease developed.
The study was published online on Friday by the journal Nature.
ZMapp had never been tested in humans before two US aid workers who got Ebola while working in Africa were allowed to try it. The rest of the limited supply was given to five others.
There is no more ZMapp now, and once a new batch is ready, it still needs some basic tests before it can be tried again during the African outbreak, Fauci said.
“We do need to know what the proper dose is” in people and that it is safe, he said.
ZMapp is three antibodies that attach to cells infected with Ebola, helping the immune system kill them.
Of the seven people known to have been treated with ZMapp, two have died — a Liberian doctor and a Spanish priest. The priest received only one of three planned doses. The two Americans recovered, as have two Africans who received ZMapp in Liberia — a Congolese doctor and a Liberian physician’s assistant, who were to be released from a treatment center yesterday.
Doctors have said there is no way to know whether ZMapp made a difference or the survivors recovered on their own, as about 45 percent of people infected in this outbreak have.
ZMapp’s maker, Mapp Biopharmaceutical Inc, of San Diego, California, has said the small supply of the drug is now exhausted and that it will take several months to make more. The drug is grown in tobacco plants and was developed with US government support.
Kobinger said it takes about a month to make 20 to 40 doses at a Kentucky plant where the drug is being produced. Officials have said they are looking at other facilities and other ways to ramp up production, and Kobinger said there were plans for a clinical trial to test ZMapp in people early next year.
The monkey study involved scientists from the Canada health agency, Mapp Biopharmaceutical, the US National Institutes of Health and the US Army Medical Research Institute of Infectious Disease.
Eighteen monkeys were given lethal amounts of Ebola in a shot, then received three intravenous doses of ZMapp, given three days apart starting three to five days after they were infected.
All treated with ZMapp survived; three other infected monkeys who did not get the drug died within eight days.
Primates have been good stand-ins for people for many viral diseases, but how well they predict human responses to Ebola, “we just don’t know,” Duke University infectious disease specialist Cameron Wolfe said.
The study also “tells us nothing about side effects” people might have, he added.
Still, it was encouraging that even monkeys with severe symptoms got better, said Wolfe and Erica Ollmann Saphire, a Scripps Research Institute professor who has worked with some of the study leaders on antibodies to Ebola.
“The treatment window in humans needs to be established in a well-controlled trial” that also would explore the correct dose of ZMapp in people, Saphire said. “Given its tremendous efficacy in the ... primates, I don’t see how it couldn’t be helpful in people.”
The Polish Supreme Court on Friday quashed a lower court’s green light for the extradition of a businessman to China for alleged fraud, a charge he has denied, saying that he is being targeted for supporting Falun Gong. Polish authorities took Chinese-born Swedish citizen Li Zhihui, now 53, into custody in 2019 on an international warrant issued by China for alleged non-payment in a business deal, Krzysztof Kitajgrodzki, his Polish lawyer, told reporters. Following the Supreme Court ruling, the case would return to a lower appellate court for review. Kitajgrodzki told reporters that it was still not a given that his client
The Palauan president-elect has vowed to stand up to Chinese “bullying” in the Pacific, saying that the archipelago nation is set to stand by its alliances with “true friends,” Taiwan and the US. Surangel Whipps Jr, 52, a supermarket owner and two-time senator from a prominent Palauan family, is to be sworn in as the new president tomorrow, succeeding his brother-in-law, Tommy Remengesau Jr. In a forthright interview, Whipps said that the US had demonstrated over the years that it was a reliable friend of Palau, most recently shown by its delivery of 6,000 doses of the Moderna COVID-19 vaccine. “It’s important for
DELIVERING HOPE: The Japanese PM pledged to push ahead with plans to stage the Games, despite polls showing about 80% think they will not or should not happen Japanese Prime Minister Yoshihide Suga yesterday vowed to get the COVID-19 pandemic under control and hold the already postponed Olympic Games this summer with ample protection. In a speech opening a new session of parliament, Suga said that his government would revise laws to make disease prevention measures enforceable with penalties and compensation. Early in the pandemic, Japan was able to keep its caseload manageable with nonbinding requests for businesses to close or operate with social distancing, and for people to stay at home, but recent weeks have seen several highs in new cases per day, in part blamed on eased attitudes
On Sunday last week, in a nondescript building in the Indian city of Gwalior, 322km south of Delhi, a large crowd of men gathered. Most wore bright saffron hats and scarves, a color evoking Hindu nationalism, and many held strands of flowers as devotional offerings. They were there to attend the inauguration of the Godse Gyan Shala, a memorial library and “knowledge center” dedicated to Nathuram Godse, the man who shot Mahatma Gandhi. The devotional yellow and pink flowers were laid around a black and white photograph of Godse, the centerpiece of the room. On Jan. 30, 1948, Godse stepped out in